Skip to main content

Table 2 Summary of assays and response rates in immune checkpoint inhibitor trials in metastatic renal cell carcinoma

From: Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

Ref CPI Drug Target Antibody for PD-L1 IHC Assay Definition of PD-L1 positivity ORR (PD-L1+) ORR (PD-L1-) ORR All Patients
[14] Single Agent Nivolumab PD-1 Rabbit 28–8 (Dako) PD-L1 ≥ 5% (TC) 45% (13/29) 18% (14/78) 25% (27/107)
[18] Single Agent Atezolizumab PD-L1 Rabbit SP142 (Ventana) IHC 1/2/3 ICa 18% (6/33) 9% (2/22) 15% (8/55)
[25] Combinationb Nivolumab and Ipilimumab PD-1 and CTLA-4 Rabbit 28–8 (Dako) PD-L1 ≥ 1% (TC) 58% (58/100) 37% (105/284) 42% (163/384)
  1. TC tumor cells, IC percentage of PD-L1 positive immune cells in the tumor microenvironment, ORR overall response rate
  2. aIHC 1 is ≥1%, IHC 2 is ≥5%, IHC 3 is ≥10%
  3. bIMDC Intermediate/poor risk